Short answer
Penumbra Inc (PEN) filed its fiscal 2015 10-K annual report with the SEC on Mar 8, 2016.
- Top risk flagged: FDA Form 483 observations in 2015: clinical-site monitoring and CAPA effectiveness checks requiring corrective actions
Penumbra Inc FY2015 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Global interventional medical-device model spanning neuro and peripheral vascular therapies for specialist physicians
- 2015 launches: ACE 64 ischemic-stroke catheter, SMART Coil, and expanded Indigo System with CAT6 and CAT8
- Peripheral vascular expansion accelerated through broader thrombectomy clearance and Lantern Microcatheter clearance in December 2015
- Revenue $186.1 million, up 48.3%; R&D $18.0 million versus $15.6 million in 2014
- New 99,568-square-foot Alameda lease expanded manufacturing and R&D capacity beyond the existing 180,000 square feet
Management Discussion & Analysis
- Revenue $186.1M, up 48.3% YoY from $125.5M, driven by salesforce expansion and product adoption
- Gross margin 66.7% vs 66.0%; operating margin 2.2% vs 2.4%; net margin 1.3% vs 1.8%
- Best segment peripheral vascular: $44.7M, up 131.9%; neuro: $141.4M, up 33.1%
- Operating cash use $22.3M; capex $5.5M; IPO proceeds $124.7M; marketable investment purchases $80.3M
- Outlook: continued R&D, manufacturing, international expansion; risks from competition, regulatory timing, foreign exchange and supplier concentration
Risk Factors
- FDA Form 483 observations in 2015: clinical-site monitoring and CAPA effectiveness checks requiring corrective actions
- International sales 31.6% of revenue, with 10.2% concentrated through Japanese distributor Medico’s Hirata
- Single Alameda campus produces substantially all products without redundant facilities, exposing operations to earthquake disruption
- Boston Scientific, Johnson & Johnson, Medtronic, Stryker and Terumo possess greater resources and competing technologies
- Neurovascular products generate most revenue, creating concentration risk if Penumbra System or Coil 400 sales decline
Generated from the filing text; verify against the original. How to read a 10-K
Other Penumbra Inc annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.